Telos(NASDAQ:TLS) reported second quarter 2025 results on August 11, 2025, delivering revenue of $36 million (up 26% year-over-year), adjusted EBITDA of $400,000 profit (versus loss guidance), and ...

Novo Nordisk's FY 2025 guidance cuts are driven by softer U.S. Wegovy/Ozempic and GLP-1 trends. Click here to find out why I ...

Cash Gross Margin-- 38.4% cash gross margin in Q2 2025, also within guidance and historical range of the last five years.